CAMBRIDGE, Mass.–(BUSINESS WIRE)–Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its second quarter 2022 financial results for the period ended June 30, 2022. “We are pleased to report continued reductions in operating expenses as we remain focused on conserving cash to ensure that we have sufficient financial resources to capture future potential … [Read more…]
Granted FDA Fast Track Designation for APC Clinical Candidate Published Comprehensive Preclinical Research on SQZ® TAC Platform in Frontiers in Immunology Presented First SQZ® Point-of-Care (POC) Manufacturing System Performance Data; Initial Clinical Use Planned for SQZ® TAC Celiac Disease Program with IND Submission Expected in First Half 2023 Strengthened Leadership with Experienced CMO and CFO … [Read more…]
FOSTER CITY, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2022 financial results after the market closes on Thursday, August 11, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as … [Read more…]
EXETER, N.H.–(BUSINESS WIRE)–Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the Canaccord Genuity … [Read more…]
CHARLOTTE, N.C.–(BUSINESS WIRE)–Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors approved a 5% increase to the company’s quarterly cash dividend to $0.21 per share of Class A common stock issued and outstanding. The cash dividend will be payable on September 15, 2022, to stockholders of record … [Read more…]
Second Quarter 2022 is Highest Product Revenue in Company History Total Revenue of $47.6 Million Grew 26% YoY in the Second Quarter Product Revenue of $41.0 Million Grew 30% YoY in the Second Quarter Reiterating Full-Year 2022 Product Revenue Guidance Range of $160-165 Million CONCORD, Calif.–(BUSINESS WIRE)–Cerus Corporation (Nasdaq: CERS) today announced financial results for … [Read more…]
– Conference Call and Webcast Today, August 4, 2022 at 4:30 p.m. ET PASADENA, Calif.–(BUSINESS WIRE)–$arwr–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2022. The company is hosting a conference call today, August 4, 2022, at 4:30 p.m. ET to discuss the results. Conference Call and … [Read more…]
Software Revenue of $30.0 Million, a 25 Percent Increase Over Second Quarter of 2021; Total Revenue of $38.5 Million, up 29 Percent Over Second Quarter of 2021 Company Maintains Full-Year 2022 Financial Outlook Phase 1 Clinical Study of SGR-1505, Schrödinger’s MALT1 Inhibitor, On-Track to Begin in the Fourth Quarter of 2022 NEW YORK–(BUSINESS WIRE)–Schrödinger, Inc. … [Read more…]
Additional Independent, Assisted and Memory Care Services Coming Soon to the East Side of Indianapolis GREENFIELD, Ind.–(BUSINESS WIRE)–Senior Living developer, Avenue Development, in partnership with Randall Residence, announces the groundbreaking of Randall Residence at Gateway Park just outside Indianapolis, Indiana. This senior living campus will consist of independent living cottages and apartments as well as … [Read more…]
AUSTIN, Texas–(BUSINESS WIRE)–Berry Consultants, LLC announced today that it is discontinuing its involvement in the I-SPY trials in neoadjuvant breast cancer. Beginning in 2009, Donald Berry, PhD, of Berry Consultants designed the I-SPY 2 trial in collaboration with trial PI Laura Esserman, MD. He has served as the trial’s co-PI since that time. Berry Consultants … [Read more…]
